How long to take sulfamethoxazole after a kidney transplant
Official title: A Controlled Study on the Prophylaxis of Pneumocystis Jirovecii Pneumonia With Fixed-dose Compound Sulfamethoxazole Tablets of Different Maintenance Durations After Renal Transplantation
Run by Anhui Provincial Hospital · NCT07231770 · Data updated 2026-11-12
This study will test whether different lengths of sulfamethoxazole (TMP‑SMX) taken after a kidney transplant better prevent Pneumocystis jirovecii pneumonia in adult transplant recipients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 450 (estimated) |
| Sponsor | Anhui Provincial Hospital Government |
| Locations | 1 site (Hefei, Anhui) |
| Status | Recruiting |
| Started | May 28, 2024 |
| Main results expected | February 28, 2026 |
| Study ends | August 8, 2027 |
| Registry record updated | December 16, 2025 |
| Trial ID | NCT07231770 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–70 who have received a kidney transplant, are HIV‑negative, have no known TMP‑SMX allergy, and can provide informed consent are ideal candidates.
✕Probably not a fit
People who are HIV‑positive, have a history of TMP‑SMX allergy, are outside the 18–70 age range, or cannot comply with follow‑up are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial enrolls adult kidney transplant recipients who will receive time-driven sulfamethoxazole (TMP‑SMX) prophylaxis according to predefined dosing schedules to compare infection outcomes. Participants will be followed clinically with testing for PJP using sputum GMS stain, direct immunofluorescence or PCR on induced sputum or BALF, and metagenomic next‑generation sequencing when indicated. The design targets the observed pattern of PJP incidence, which shows a peak around 9 months and a second peak between 10 and 15 months after transplantation. The goal is to clarify an optimal prophylaxis duration where current guideline recommendations and clinical practice vary.
Why it matters
Potential benefit: If successful, the study could define an optimal TMP‑SMX prevention period that reduces PJP cases while avoiding unnecessary prolonged antibiotic use.
How similar studies have gone: Previous studies have reported PJP occurring more than one year post‑transplant and have used varying prophylaxis durations, so the optimal course remains unsettled.
Who can join: the full rules
Show full inclusion / exclusion criteria
Diagnostic Criteria for PJP (meeting one of the following criteria is sufficient): 1. Detection of Pneumocystis jirovecii via sputum Gomori methenamine silver (GMS) stain. 2. According to guidelines/consensus: Positive direct immunofluorescence assay and/or positive polymerase chain reaction (PCR) assay on induced sputum or bronchoalveolar lavage fluid (BALF) specimens. 3. Detection of Pneumocystis jirovecii strains in sputum, blood, or bronchoalveolar lavage fluid (BALF) by metagenomic next-generation sequencing (mNGS). Inclusion Criteria: * Subjects must meet all the following conditions to be enrolled: (1) Age: 18-70 years old; (2) Post-renal transplantation; (3) Voluntarily participate in this clinical study, be able to cooperate with researchers to conduct the study, and sign the informed consent form. Exclusion Criteria: * Criteria: Subjects with any of the following conditions shall be excluded from the trial: (1) HIV-positive; (2) History of TMP-SMX allergy; (3) Glucose-6-phosphate dehydrogenase (G6PD) deficiency; (4) Megaloblastic anemia; (5) Multiorgan transplantation; (6) Complicated with tumor; (7) Complicated with connective tissue disease; (8) Pregnant patients.
Where it's running
-
No. 17, Lujiang Road, Luyang District, Hefei City, Anhui Province, China
Hefei, Anhui, China Recruiting
Study contacts
- Study coordinator: Xuqin Jiang
- Email: xqjiang@ustc.edu.cn
- Phone: 13675605989
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if Buzzy and virtual reality help kids get IV lines faster
This study tests whether a vein-imaging device plus virtual reality or the same device plus a pain-reducing tool can make peripheral IV placement easier for children aged 7–12 with fever.
-
Triage performance and physiological predictors of serious illness in febrile children in the pediatric emergency department
This study tests whether the initial color-coded triage category and vital signs at triage can predict serious outcomes in febrile children who come to pediatric emergency departments in Turkey.
-
Turning anonymous symptom descriptions into structured biological signals with OpenGenome
This project tries to turn adults' anonymous free-text symptom descriptions submitted to OpenGenome into structured, literature-grounded biological signals using PubMed and ClinicalTrials.gov sources and a constrained reasoning model.
-
Safety of giving an RSV preventive antibody with routine childhood vaccines
This trial will test whether giving an RSV preventive antibody at the same visit as routine childhood vaccines is as safe for infants 6 to <30 weeks old as giving the antibody at a separate visit.
-
Providing weight-based prescriptions for fever medicine to reduce emergency department return visits for young children.
This will test if giving caregivers weight-based prescriptions for acetaminophen and ibuprofen to children aged 6 to 35 months when they leave the ED reduces unscheduled return visits within one week.
-
Point-of-care fingertip CRP testing to guide care for febrile children
We will test a small fingertip (capillary) C‑reactive protein (CRP) test in primary care to help doctors decide care for children with fever who need a CRP measurement.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.